company background image
MLAB

Mesa LaboratoriesNasdaqGS:MLAB Stock Report

Last Price

US$299.25

Market Cap

US$1.6b

7D

0.1%

1Y

2.2%

Updated

19 Jan, 2022

Data

Company Financials +
MLAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance2/6
Financial Health5/6
Dividends0/6

MLAB Stock Overview

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally.

Mesa Laboratories Competitors

STERIS

NYSE:STE

US$23.2b

Merit Medical Systems

NasdaqGS:MMSI

US$3.1b

Utah Medical Products

NasdaqGS:UTMD

US$335.9m

Price History & Performance

Summary of all time highs, changes and price drops for Mesa Laboratories
Historical stock prices
Current Share PriceUS$299.25
52 Week HighUS$333.42
52 Week LowUS$232.88
Beta0.35
1 Month Change-6.99%
3 Month Change-1.24%
1 Year Change2.20%
3 Year Change37.10%
5 Year Change147.64%
Change since IPO9,671.43%

Recent News & Updates

Dec 08
We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

We Think Mesa Laboratories (NASDAQ:MLAB) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

MLABUS Medical EquipmentUS Market
7D0.1%-4.8%-4.6%
1Y2.2%-0.4%7.7%

Return vs Industry: MLAB exceeded the US Medical Equipment industry which returned 0.8% over the past year.

Return vs Market: MLAB underperformed the US Market which returned 10.2% over the past year.

Price Volatility

Is MLAB's price volatile compared to industry and market?
MLAB volatility
MLAB Average Weekly Movement3.2%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: MLAB is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: MLAB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1982506Gary Owenshttps://www.mesalabs.com

Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Europe, Asia, North America, and internationally. The company’s Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry.

Mesa Laboratories Fundamentals Summary

How do Mesa Laboratories's earnings and revenue compare to its market cap?
MLAB fundamental statistics
Market CapUS$1.56b
Earnings (TTM)US$5.09m
Revenue (TTM)US$142.90m

307.0x

P/E Ratio

10.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MLAB income statement (TTM)
RevenueUS$142.90m
Cost of RevenueUS$52.59m
Gross ProfitUS$90.30m
ExpensesUS$85.21m
EarningsUS$5.09m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.97
Gross Margin63.20%
Net Profit Margin3.56%
Debt/Equity Ratio42.3%

How did MLAB perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

65%

Payout Ratio

Does MLAB pay a reliable dividends?

See MLAB dividend history and benchmarks
When do you need to buy MLAB by to receive an upcoming dividend?
Mesa Laboratories dividend dates
Ex Dividend DateFeb 25 2022
Dividend Pay DateMar 15 2022
Days until Ex dividend36 days
Days until Dividend pay date54 days

Does MLAB pay a reliable dividends?

See MLAB dividend history and benchmarks

Valuation

Is Mesa Laboratories undervalued compared to its fair value and its price relative to the market?

307.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: MLAB ($299.25) is trading above our estimate of fair value ($213.28)

Significantly Below Fair Value: MLAB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MLAB is poor value based on its PE Ratio (307x) compared to the US Medical Equipment industry average (46.7x).

PE vs Market: MLAB is poor value based on its PE Ratio (307x) compared to the US market (17x).


Price to Earnings Growth Ratio

PEG Ratio: MLAB is poor value based on its PEG Ratio (8.7x)


Price to Book Ratio

PB vs Industry: MLAB is overvalued based on its PB Ratio (3.9x) compared to the US Medical Equipment industry average (3.5x).


Future Growth

How is Mesa Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

35.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLAB's forecast earnings growth (35.2% per year) is above the savings rate (2%).

Earnings vs Market: MLAB's earnings (35.2% per year) are forecast to grow faster than the US market (13% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MLAB's revenue (11.8% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: MLAB's revenue (11.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MLAB's Return on Equity is forecast to be low in 3 years time (10.9%).


Past Performance

How has Mesa Laboratories performed over the past 5 years?

-25.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MLAB has high quality earnings.

Growing Profit Margin: MLAB became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: MLAB's earnings have declined by 25.7% per year over the past 5 years.

Accelerating Growth: MLAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: MLAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: MLAB's Return on Equity (1.3%) is considered low.


Financial Health

How is Mesa Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: MLAB's short term assets ($319.4M) exceed its short term liabilities ($28.7M).

Long Term Liabilities: MLAB's short term assets ($319.4M) exceed its long term liabilities ($181.0M).


Debt to Equity History and Analysis

Debt Level: MLAB has more cash than its total debt.

Reducing Debt: MLAB's debt to equity ratio has reduced from 58.4% to 42.3% over the past 5 years.

Debt Coverage: MLAB's debt is well covered by operating cash flow (22.8%).

Interest Coverage: MLAB's interest payments on its debt are not well covered by EBIT (2x coverage).


Balance Sheet


Dividend

What is Mesa Laboratories's current dividend yield, its reliability and sustainability?

0.21%

Current Dividend Yield


Upcoming Dividend Payment

TodayJan 20 2022Ex Dividend DateFeb 25 2022Dividend Pay DateMar 15 202218 days from Ex DividendBuy in the next 36 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: MLAB's dividend (0.21%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.35%).

High Dividend: MLAB's dividend (0.21%) is low compared to the top 25% of dividend payers in the US market (3.48%).


Stability and Growth of Payments

Stable Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: MLAB is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Gary Owens (53 yo)

4.33yrs

Tenure

US$2,557,718

Compensation

Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as...


CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD2.56M) is below average for companies of similar size in the US market ($USD3.70M).

Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MLAB's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: MLAB's board of directors are considered experienced (5.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MLAB insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

Mesa Laboratories, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Mesa Laboratories, Inc.
  • Ticker: MLAB
  • Exchange: NasdaqGS
  • Founded: 1982
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$1.564b
  • Shares outstanding: 5.23m
  • Website: https://www.mesalabs.com

Number of Employees


Location

  • Mesa Laboratories, Inc.
  • 12100 West Sixth Avenue
  • Lakewood
  • Colorado
  • 80228
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:34
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.